Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis

Microbial Drug Resistance

Volumn 6, Issue 2, 2000, Pages 155-161

  Cross, E W ^a   Park, S ^a   Perlin, D S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BUTOCONAZOLE; CLOTRIMAZOLE; FLUCONAZOLE; MICONAZOLE; MONISTAT 3; MONISTAT 7; MYCELEX 3; MYCELEX 7; NON PRESCRIPTION DRUG; PYRROLE DERIVATIVE; TIOCONAZOLE; VAGISTAT 1;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CROSS RESISTANCE; DISEASE EXACERBATION; FEMALE; HUMAN; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SELF MEDICATION; SEROTYPE; VAGINITIS;

EID: 0033857753     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/107662900419474     Document Type: Article

References (45)

1. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches
2. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450
3. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
4. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis
5. Prior fluconazole exposure as an independent risk factor for fluconazole-resistant candidosis in HIV positive patients: A case-control study
6. Immunopathogenesis of recurrent vulvovaginal candidiasis
7. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans
8. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains
9. Chronic vulvo-vaginal glabrata candidiasis: Characteristics of women with Candida albicans, Candida glabrata and no Candida
10. Fluconazole resistance in Candida glabrata
11. Azole drug resistance in yeasts
12. Update on antifungal resistance
13. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options
14. In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network
15. The mutation T315A in Candida albicans sterol 14-alpha demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity
16. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
17. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients
18. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates
19. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
20. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
21. Molecular biological characterization of an azole-resistant Candida glabrata isolate
22. Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata
23. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis
24. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
25. Drug resistance in tuberculosis
26. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission
27. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
28. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic
29. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates
30. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
31. National epidemiology of mycoses survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species
32. Multidrug-resistant Mycobacterium tuberculosis: Molecular perspectives
33. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis
34. Resistance of Candida species to fluconazole
35. 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents
36. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
37. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
38. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
39. Limitations of antifungal agents in the treatment of Candida vaginitis: Future challenges
40. Vaginitis
41. Vulvovaginitis due to Candida glabrata. An emerging problem
42. Vulvovaginitis. When Candida becomes a problem
43. Nosocomial Candida glabrata colonization: An epidemiologic study
44. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: The emergence of Candida glabrata?
45. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus